Trade name of the drug: Felodipine SR.


Active ingredient (INN): Felodipine.


Dosage forms: Coated tablets, with a sustained release of 5 mg and 10 mg in blisters.


Pharmacotherapeutic group: Antihypertensive agents (calcium channel blockers).


Pharmacological properties: The drug belongs to the calcium channel blockers of the dihydropyridine group. It has antihypertensive and antianginal effects. It lowers blood pressure by reducing peripheral vascular resistance. It has a dose-dependent anti-ischemic effect. It reduces the magnitude of myocardial infarction; protects against reperfusion complications. Generally, it does not have negative inotropic effects, and has minimal effect on the cardiac conduction system.


Pharmacokinetics: Sustained extrication of felodipine from the coated tablets, leads to elongation of drug absorption phase and provides a uniform concentration of felodipine in blood plasma within 24 hours. Felodipine is almost completely absorbed from the gastrointestinal tract. Bioavailability does not depend on the dose within the therapeutic range, and is about 15%. 99% of felodipine forms bonds with plasma proteins, first of all with albumins.
Felodipine is completely metabolized by the liver, and all its metabolites are not active. Effective half-life of felodipine is of 25 hours. Prolonged use does not lead to accumulation of felodipine.

Pharmacokinetics in special patient groups: In elderly patients, and in cases of liver function abnormalities, plasma concentration of felodipine is higher than that in younger patients. Pharmacokinetic indicators of felodipine remain unchanged in patients with impaired renal function, including those receiving hemodialysis. About 70% of the dose taken is excreted with urine, and the remainder with faeces in the form of metabolites. An unaltered form is eliminated in quantities inferior to 0.5% of the dose with urine. Felodipine penetrates the blood-brain barrier, enters the placenta and is excreted with breast milk.


Directions for usage:
— Arterial hypertension;
— Stable angina (including Prinzmetal angina).


Dosage and method of administration: The drug shall be taken in the morning, before breakfast or after a light breakfast. Do not chew, crush or divide film-coated tablets.


Arterial hypertension. Adults (including the elderly): Dosage is always determined individually. Therapy begins with a dose of 5 mg, once a day. If necessary, the dosage may be increased; usually, the maintenance dose is 5-10 mg once, daily. To determine the individual dose, it is advisable to use tablets containing 2.5 mg of Felodipine. For the elderly patients or patients with impaired renal function, the recommended starting dose is 2.5 mg once a day.


Stable angina. Adults: The dosage is always determined individually. Treatment begins with a dose of 5 mg once a day, if necessary, the dose can be increased to 10 mg once a day. The maximum daily dose is 20 mg once a day.

The drug may be used in combination with beta-blockers, angiotensin-converting enzyme (ACE) inhibitors or diuretics. Complex therapy usually increases the hypotensive effect of the drug. Therefore, it is necessary to be aware of the increased risk of arterial hypotension. Therapeutic dose should be reduced in patients with severely impaired liver function. In patients with impaired renal function, the pharmacokinetics of the drug is not significantly changed.


Side effects: As in the usage of other calcium channel blockers, the drug can cause facial flushing, headaches, palpitations, dizziness and fatigue. These reactions are reversible and often occur during early treatment or when the dose is increased. Also, depending on the dose, a peripheral edema may occur, which may result in precapillary vasodilation. In patients with gingival inflammation or periodontitis, a light swelling of the gums may occur. This can be prevented by careful observance of oral hygiene. And in some cases: skin: rarely – urticaria and itching. In isolated cases, photosensitivity reactions; musculo-skeletal system: in isolated cases, arthralgia and myalgia; central and peripheral nervous system: headache, dizziness. In rare cases, paresthesia; gastrointestinal tract: rarely – nausea, gingival hyperplasia; liver: in rare cases elevated liver enzymes; cardiovascular system: rarely – tachycardia, palpitation, peripheral edema; other: rarely – fatigue, in isolated cases – hypersensitivity reactions such as angioedema.


— Unstable angina;

— Acute myocardial infarction, and within one month after old myocardial infarction;

— Cardiogenic shock;

— Clinically significant aortic stenosis;

— Hypersensitivity to Felodipine or other dihydropyridines;

— Pregnancy and lactation period;

— Heart failure in decompensation stage;

— Severe hypotension;

— Children under the age of 18.



Drug interactions: Felodipine increases the concentration of digoxin in plasma, but the dosage can remain unchanged.
Inhibitors of cytochrome P450 (e.g. cimetidine, erythromycin, itraconazole, ketoconazole) slow metabolism of felodipine in the liver, increasing the blood-plasma concentration of the drug.
Inductors for microsomal enzymes (phenytoin, carbamazepine, rifampicin, barbiturates) reduce the concentration of felodipine in blood plasma.
Nonsteroidal anti-inflammatory drugs do not weaken the hypotensive effect of felodipine.

The high rate of felodipine bonding with proteins does not affect free fraction bonding with other drugs (eg, warfarin). Do not use the drug with a grapefruit juice due to the flavonoids that it contains, that enhances bio-availability of felodipine. Beta adrenoblockers, verapamil. tricyclic antidepressants and diuretics enhance the hypotensive effect of felodipine.


Special instructions: In rare cases, the drug as well as other vasodilators, can cause acute arterial hypotension – which, in a number of sensitive patients, can lead to myocardial ischemia. Currently there is no data on the appropriateness of the usage of the drug as a secondary prevention of myocardial infarction.
It is effective and well-tolerated by patients, regardless of gender and age, as well as patients with concomitant diseases such as asthma and other lung diseases; impairment of renal function; diabetes; gout; hyperlipidemia; Raynaud’s syndrome, and after lung transplantation.

Has no effect on the blood concentration of glucose and lipid pattern.
Patients, who during Felodipine treatment, experience weakness and dizziness, should stop driving vehicles or performing tasks that require attention and concentration.

Keep out of the reach of children and do not use it after the expiry date.


Overdose: Symptoms: possible severe arterial hypotension and bradycardia. Treatment: symptomatic therapy. When experiencing severe arterial hypotension, the patient should be laid in a horizontal position, with their legs up. In case of bradycardia, a dose of 0.5 mg -1 atropine is prescribed by intravenous administration. If this is insufficient, it is necessary to increase the volume of plasma levels by infusion of glucose solution, sodium chloride or dextran. Symptomatic drugs with predominant effect on the alpha-adrenergic receptors are prescribed in the event that the above measures prove ineffective.


Storage conditions: Keep dry, avoid exposure to direct sunlight, at a temperature not exceeding 25 ° C.


Shelf life: 2 years.


Dispensing requirements: On prescription


Manufacturer: Codepharm LLC (IE), 30-Gulistan Str, 4th quarter, Gulistan, Sirdaryo Region, The Republic of Uzbekistan.

Add Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Axborot byulleteni

[mc4wp_form id="375"]

Get the latest updates and news

KSE-design © 2024 All rights reserved.